Clinical Trial

Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities

Study acronym: AMPLIFIED
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-06
Trial Details
NCT Number NCT06794996
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Proteinuric Kidney Disease
Enrollment 42 participants
Start Date 2025-02-04
Primary Completion 2026-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-05